Antibacterial activity and safety of commercial veterinary cationic steroid antibiotics and neutral superoxidized water

Benjamin E. Bergstrom¹, Ahmed Abdelkhalek², Waleed Younis², G. Kenitra Hammac², Wendy M. Townsend¹*, Mohamed N. Seleem²

¹ Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America, ² Department of Comparative Pathobiology, College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, United States of America

*townsenw@purdue.edu

Abstract

Antibiotic resistance of bacteria common to the ocular surface is an evolving problem. Thus, novel treatment options with new modes of action are required. We investigated the antibacterial activity and safety of three commercially available topical veterinary ophthalmic products (cationic steroid antibiotics, products A and B, and a neutral superoxidized water, product C) to determine their potential use as antimicrobial alternatives. The minimum inhibitory concentrations (MIC) of the three products were determined against 17 antibiotic resistant bacterial clinical isolates from the ocular surface. Using a standard cytotoxicity assay, the products at varying concentrations were evaluated with a corneal fibroblast cell line and a macrophage-like cell line to determine their potential toxic effect in vitro. The commercial ophthalmic solutions, ofloxacin 0.3%, tobramycin 0.3% and gentamicin 0.3% were used as positive controls for the MIC and tobramycin 0.3% was used as positive control for the cytotoxicity assays. For the MIC, Product C showed no inhibition of growth for any organisms, while Products A and B showed inhibition of growth similar to slightly less than the positive controls. For the cytotoxicity assays, Product C exhibited minimal toxicity while Products A and B exhibited toxicity similar to the controls. In conclusion, Product C had no antibacterial activity in these assays, while Products A and B had antibacterial profiles similar to slightly less than common topical ophthalmic antibiotics and cytotoxicity profiles similar to common topical ophthalmic antibiotics. To our knowledge, this is the first report on the antibacterial activity and safety of the cationic steroid antibiotics and superoxidized water.

Introduction

Multi-drug resistant organisms of the corneal and conjunctival surfaces are a growing concern in numerous veterinary species [1–5]. Recently, a study investigating the antimicrobial resistance of 49 isolates of Staphylococcus pseudintermedius from the eyes of dogs with and without ocular disease concluded that fluoroquinolone resistance was increasing. Eighteen of 49 isolates were mec-A positive, 16 of which were also oxacillin resistant. Nine of the mec-A positive
were resistant to more than one fluoroquinolone [1]. In another study investigating the prevalence of MRSA-associated keratitis in dogs, 71 Staphylococcus strains were isolated. Twenty-four percent of those strains were methicillin resistant [2]. The increasing prevalence of multidrug resistant bacteria illustrates the need for antimicrobial agents targeting novel sites to circumvent resistance.

One appealing target is the bacterial membrane since resistance to membrane-targeting antibiotics would require major changes in bacterial structure. The absence of the target in the mammalian genome is also desirable because bacterial membrane-targeting antimicrobials should therefore not interfere with essential mammalian functions [6–9].

Antimicrobial peptides (AMPs) target the bacterial cell membrane and are produced by the innate immune system. AMPs typically consist of a short chain of 12 to 100 amino acids linked by peptide bonds [10]. They are most often cationic (with at least two positive charges) which permits their interaction with negatively charged components present in the bacterial membrane and cell wall. AMPs are also amphipathic, which allows them to target and penetrate bacterial cell membranes [11–15]. Since their discovery, over 2700 antimicrobial peptides have been isolated. Unfortunately, despite the success in isolating AMPs, they are very sensitive to temperature, expensive to manufacture in bulk, and selecting appropriate packaging material and storage conditions to enhance shelf life and stability is an ongoing struggle [11, 16].

Similar to AMPs, some peptide antibiotics such as polymyxin B, also target the bacterial membrane. Polymyxin B has been characterized as selectively binding lipid A, the primary constituent of the outer membranes of Gram-negative bacteria, and this peptide antibiotic is highly active against most strains of bacteria producing lipid A [17–20]. Polymyxin B is also considered facially amphipathic, meaning it contains side chains from hydrophobic residues on one face of a molecule and cationic side chains on the opposing face [7, 21]. In recent years, a class of cationic steroid antibiotics (CSAs) was developed with the intent of mimicking the antibacterial activities of polymyxin B [17, 22]. These compounds, prepared from cholic acid with carbohydrates appended on one face of the molecule, were shown to facilitate the movement of polar compounds across eukaryotic membranes [23]. Since their development, several studies have evaluated various CSAs to determine the antibacterial efficacies of the individual compounds. One CSA in particular, CSA-13, has been shown to have potent broad-spectrum antimicrobial activity [10, 24–31]. Where AMPs have fallen short in their capacity for large-scale production, CSAs have succeeded. CSA-13 has been manufactured into formulations for commercial veterinary use and is currently marketed as Products A and B. The concentration of the active CSA-13 in these products is 0.04%. Although marketed under different names, the products appear to be the same formulations as determined by a personal communication with the product developer.

Another antimicrobial alternative currently being investigated is neutral superoxidized water (SOW). Super-oxidized waters have historically been used as disinfectants in hospitals and are produced as either acidic (pH 2–4) or alkaline (pH ≥ 9) solutions [32–35]. Unfortunately, acidic and alkaline SOWs are very corrosive, unstable due to very short half-lives, and unsafe for medicinal and therapeutic use [32, 36]. More stable, neutral SOWs have therefore been investigated as antimicrobials and wound irrigants due to their improved tissue compatibility [32, 35, 37–43]. Neutral SOWs are electrochemically processed aqueous solutions manufactured from pure water and salt. Electrical energy is used to produce a charge in the aqueous solution resulting in a solution rich in reactive oxygen species, a neutral pH, and a longer half-life (> 12 months) than other super-oxidized solutions such as bleach [38, 44]. The chemically active oxychlorine compounds in neutral SOW, hypochlorous acid and sodium hypochlorite, exist in equilibrium to produce solutions with high efficacy against microorganisms while maintaining product stability and low toxicity [32]. The mechanism by which SOWs are
Antimicrobial has not been fully defined, but is thought to be similar to the respiratory burst phenomenon displayed by phagocytic leukocytes. Briefly, when bacteria are engulfed by neutrophils, the neutrophils rapidly produce and release reactive oxygen species that lead to the formation of hypochlorous acid. Hypochlorous acid is the main active ingredient in neutral SOW. The neutral charge of the hypochlorous acid molecules draw them to the positively charged bacterial cell membrane. The hypochlorous acid molecules penetrate the membrane, enter the cell, and begin disrupting the normal metabolic functions of the bacteria. Cell lysis occurs via the osmotic pressure imbalance between the cell and the hypotonic SOW solution. Using contrast microscopy, bacterial swelling was observed within the first 30 seconds of exposure to SOW followed by bacterial cell rupture [45]. One such neutral SOW, commercially manufactured for the veterinary market, is Product C. The total free available chlorine in the commercial solution ranges from 110 to 150 parts per million (ppm) and the main active ingredient, hypochlorous acid, is present at a concentration of 0.015%.

To our knowledge, there are no data on the antibacterial activity and safety of the CSAs, Products A and B, and the neutral SOW, Product C, as their commercial, over the counter, veterinary formulations. These products are not animal drugs approved by the FDA. Instead they are considered to be homeopathic due to the very low concentrations of active ingredients. Homeopathic products are minimally regulated by the FDA and there is no requirement to demonstrate efficacy, lack of toxicity, or stability.

In the present study, we investigated the antibacterial activity of these three commercial, over the counter, veterinary formulations against clinical bacterial isolates and the toxicity in two different mammalian cell lines. If proven safe and effective, their use as antimicrobial alternatives could be further investigated in the efforts to limit antibiotic use and combat antimicrobial resistance.

Materials and methods

Commercial products, antibiotics and reagents

The cationic steroid antibiotics, Products A and B, (both products contain cholan-24-oic acid, 3,7,12-tris[3-amino-1-oxoproxy]-octyl ester [3 alpha,5 beta,7 alpha,12 alpha]-[CSA-13 0.04%], polysorbate 20, hydroxypropyl methylcellulose, water); neutral superoxidized water, Product C (contains hypochlorous acid [0.0150%], electrolyzed water, sodium chloride, phosphates, sodium hypochlorite); and ophthalmic antibiotic solutions, ofloxacin 0.3%, (Akorn Inc., Lake Forest, IL, USA), tobramycin 0.3% (Bausch & Lomb Inc., Tampa, FL, USA) and gentamicin 0.3% (Bausch & Lomb Inc., Tampa, FL, USA), were all purchased from commercial vendors. Mueller-Hinton broth (MHB) was purchased from Sigma-Aldrich.

Bacterial isolates

Seventeen total clinical bacterial isolates of different bacterial strains (4 Moraxella spp., 1 Neisseria spp., 3 Pseudomonas spp., 5 Staphylococcus spp. and 4 Streptococcus spp.) were included in this study. All isolates, except the Moraxella spp., were identified at the Indiana Animal Disease Diagnostic Laboratory from specimens collected from canines admitted to the Purdue University Veterinary Teaching Hospital. All canine isolates were considered multi-drug resistant. The Moraxella spp. isolates were obtained and identified at the Veterinary Diagnostic Center at the University of Nebraska from infectious bovine keratoconjunctivitis. Briefly, swabs were streaked onto tryptic soy agar containing 5% sheep’s blood and incubated for 18–24 hr at 37˚C with 5% CO2 supplementation. Bacterial colonies with morphology consistent with members of the genus Moraxella were further screened for oxidase production. Colonies positive for oxidase production were then subjected to Gram staining and were subcultured...
for purity. All subcultured organisms that were characterized as Gram-negative rods or cocco-
bacilli by Gram stain were subjected to molecular speciation. Isolates were subsequently identi-
fied as M. bovis based on a polymerase chain reaction (PCR) assay and a subsequent
restriction fragment length polymorphism analysis that targets the 16S-23S intergenic spacer
region in combination with phenotypic tests as needed [46]. A description of the clinical iso-
lates used in the study can be found in the Supplemental Table (S1 Table).

Antibacterial assays
The broth microdilution technique was used to determine the minimum inhibitory concentra-
tions (MIC) of the commercial products and antibiotics in Mueller Hinton Broth (MHB)in
accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines with few
modifications [47]. MIC assays were carried out with an initial bacterial inoculum of 5 x 10^5
colony forming unit (CFU/ml). Commercial products and antibiotics were added to Poly-
sterene 96-well plates (Corning, Corning, NY, USA) different concentrations, serially diluted and
plates were incubated for 24 hr. at 37˚C. MIC was defined as the lowest concentration of com-
mercial product or antibiotic that inhibited the visible growth of bacteria. MIC was done in
triplicate and the highest value was reported. To standardize results, minimum inhibitory con-
centrations were calculated in μg/ml from the original dilutions of each of the original com-
mercial products because the starting concentrations of the active ingredients in each of the
products were different from one another. For example, the commercial antibiotics (Tobramy-
cin, Gentamicin, Ofloxacin) have a 0.3% concentration of their respective antibiotic whereas
the cationic steroid antibiotics (Products A and B) have a 0.04% concentration of CSA-13 and
Product C has a 0.015% concentration of hypochlorous acid. For the Moraxella and Streptococ-
cus spp. strains, 5% sheep’s blood was added to the growth media.

Cytotoxicity analyses
Commercial products were assayed at concentrations of 6.25%, 12.5%, 25%, 50% and 100%
against a murine macrophage-like cell line (J774A.1) and a rabbit corneal fibroblast cell line
(CCL-60) to determine the potential toxic effects in vitro. The J774A.1 line was used to evaluate
possible effects of the topical medications if they are absorbed systemically and the CCL-60 line
was used to evaluate direct effects on the corneal surface. Briefly, J774A.1 cells were seeded at a
density of 1.5 x 10^4 per well in a tissue culture treated 96-well plate (Corning, Corning, NY,
USA) in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), and incubated at 37˚C in a 5% CO_2 atmosphere for 24 hours. Similarly, the CCL-
60 cells were seeded at a density of ~2 x 10^4 cells per well in a tissue culture treated 96-well plate,
also suspended in DMEM supplemented with 10% FBS and incubated at 37˚C in a 5% CO_2
atmosphere for 24 hours. The compounds were added in triplicate and incubated at differing
intervals for different assays, a single 2-hour interval and four 5-minute intervals. For the multi-
ple exposures, the cells were washed, new media was added, and the cells were incubated for 1
hour before re-addition of the compound. The 5-minute intervals were used to simulate the
amount of time a drop would likely remain on the surface of the eye before being washed away
by the tear film. The multiple time points were used to simulate the number of times per day an
eye drop would likely be used in a clinical setting. The cells were treated with commercial prod-
ucts at concentrations ranging from their initial marketed concentration to 0.8% of the initial
concentration. Untreated cells were used as a negative control. Tobramycin 0.3% ophthalmic
solution was used as a positive control. After incubation, the cells were washed three times with
PBS and the media in each well was replaced with 100 μL of DMEM media and 20% of the assay
reagent, MTS 3-((4,5-dimethylthiazol-2-yl)-5-((3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-

tetrazolium) (Promega, Madison, WI, USA). The cells were incubated further for 4 hours at 37˚C in 5% CO₂. Corrected absorbance readings were taken using a kinetic ELISA microplate reader (Molecular Devices, Sunnyvale, CA, USA). Cell viability was expressed as percentage of absorbance in comparison to the control, PBS.

**Statistical analyses**

Cytotoxicity data were analyzed using two-way ANOVA with Holm-Sidak’s multiple comparisons test using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). P-values of < 0.05 were considered significant.

**Results**

**Antibacterial assays**

The bacterial species and MICs for each of the compounds are shown in Table 1. For the *Moraxella* spp., Products A and B showed similar, moderate inhibitory activity. Product C caused no inhibition of growth. The commercial antibiotics, however, showed potent inhibitory activity against all of the *Moraxella* spp. isolates. For the single *Neisseria* sp. isolate, the CSAs were less effective than the commercial antibiotics while Product C showed no inhibition of growth. For the *Pseudomonas* spp., the CSAs and the commercial antibiotics demonstrated potent inhibitory activity. Product C, showed no inhibition of growth of any of the *Pseudomonas* organisms. For the *Staphylococcus* spp., both Products A and B showed inhibitory activity similar to the commercial antibiotics, which demonstrated moderate inhibitory activity. Product C showed no inhibition of growth to any of the *Staphylococcus* organisms at the concentration tested. For the *Streptococcus* organisms both CSAs demonstrated moderate inhibitory activity.

Table 1. Minimum inhibitory concentrations (μg/ml) of Products A, B, C and commercial topical ophthalmic products against bacterial isolates.

| Strain                       | MICs of the tested preparation in μg/ml |
|------------------------------|----------------------------------------|
|                              | Strain A | B  | C  | Tobramycin | Gentamicin | Ofloxacin |
| *Moraxella bovis 80–2013000742* | 0.78     | ≥ 6.25 | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |
| *Moraxella bovis 36–2012001922* | 6.25     | 6.25   | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |
| *Moraxella bovis 120–2014002878* | 6.25     | ≥ 6.25 | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |
| *Moraxella bovis 42–2012003587* | 6.25     | ≥ 6.25 | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |
| *Neisseria* spp. isolate 1   | 6.25     | 6.25   | ≥ 1500 | ≤ 11.7  | ≤ 11.7 | ≤ 11.7 |
| *Pseudomonas aeruginosa* 15442 | 6.25     | 6.25   | ≥ 1500 | ≤ 0.36 | 0.73   | 0.73   |
| *Pseudomonas aeruginosa* isolate 1 | 6.25     | 6.25   | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |
| *Pseudomonas aeruginosa* isolate 2 | 25       | 6.25   | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | 5.8    |
| *Staphylococcus aureus* isolate 1 | 6.25     | 6.25   | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |
| *Staphylococcus aureus* isolate 2 | 6.25     | 6.25   | ≥ 1500 | 0.73    | 0.73   | ≤ 0.36 |
| *Staphylococcus pseudintermedius* Case one | 3.13     | 6.25   | ≥ 1500 | 11.7    | 23.4   | 23.4   |
| *Staphylococcus pseudintermedius* Case two | 3.13     | 3.13   | ≥ 1500 | ≤ 11.7  | ≤ 0.391 | ≤ 0.391 |
| *Streptococcus canis* isolate 1 | 12.5     | ≥ 6.25 | ≥ 1500 | 5.8     | 2.9    | 0.73   |
| *Streptococcus canis* isolate 2 | 12.5     | ≥ 6.25 | ≥ 1500 | 11.7    | 5.8    | 0.73   |
| *Streptococcus canis* isolate 3 | 12.5     | 6.25   | ≥ 1500 | 5.9     | 2.9    | 1.5    |
| *Streptococcus canis* isolate 4 | 6.25     | ≥ 6.25 | ≥ 1500 | 11.7    | 5.8    | 0.73   |
| *Streptococcus schleiferi* isolate 1 | 0.78     | ≥ 6.25 | ≥ 1500 | ≤ 0.36 | ≤ 0.36 | ≤ 0.36 |

All MIC values are recorded in μg/ml. Concentrations were calculated from the dilutions of the active ingredient in each of the original commercially available products.

https://doi.org/10.1371/journal.pone.0193217.t001
compared to the commercial antibiotics, which showed potent inhibitory activity. Product C showed no inhibition of growth for any of the *Streptococcus* organisms.

**Cytotoxicity analyses**

Results for the cytotoxicity analyses are shown in Figs 1–4. In the single 2-hour assay using the J774A.1 cells, both Products A and B were less toxic than tobramycin 0.3% (Fig 1). In the single 2-hour assay using the CCL-60 cells, Product B was less toxic than Product A and tobramycin 0.3% (Fig 2). In the four 5-minute interval exposure assay using the J774A.1 cells, all three products (A, B and tobramycin 0.3%) exhibited similar toxicities at dilutions of 6.25% and greater (Fig 3). In the four 5-minute interval exposure assay using the CCL-60 cells, products A and B were more toxic than tobramycin 0.3% exhibiting toxicities at dilutions of 50% or greater (Fig 4). In both of the single 2-hour exposures using the J774A.1 cells and the CCL-60, Product C exhibited no toxicity at dilutions < 100% (Figs 1 and 2). For the four 5-minute interval exposures using the J774A.1 cells and CCL-60 cells, Product C exhibited no toxicity at dilutions ≥ 50% (Fig 3) and no toxicity at dilutions ≥ 100% (Fig 4), respectively.

**Discussion**

In this model Products A and B showed an inhibition of growth similar to and slightly less than the positive controls, while Product C was unable to inhibit growth of any of the bacteria common to the ocular surface. Products A and B exhibited toxicities similar to the positive controls, while Product C exhibited minimal toxicity. These products were chosen because of their commercial availability in the veterinary market.

---

**Toxicity to J774A.1 cells (Single 2 hour exposure)**

**Compounds**

6.25% 12.5% 25% 50% 100% Control

Fig 1. Cytotoxicity of ophthalmic products against J774A.1 cells, single 2-hour exposure. Tobramycin was used as the positive control. Cells were exposed to the commercial products for a single 2-hour exposure. Cell viability was expressed as percentage of absorbance in comparison to the negative control. A compound was considered toxic to the cell line in this experiment if ≤ 95% cell survival was recorded. Toxicity is indicated by (*).
Previous studies have demonstrated that CSA-13, as a raw compound, was very active against both Gram-positive and Gram-negative bacteria. Chin et al. measured the MIC of CSA-13 against clinical isolates of *S. aureus* [25]. The MIC values achieved in that study ranged from 1–2 μg/ml. In the present study, *S. aureus* was inhibited at a concentration of 6.25 μg/ml by Products A and B, a higher MIC than was achieved in the Chin et al. study. Moscoso et al. evaluated the inhibitory activity of CSA-13 against various *Streptococcus* spp. [48]. MIC results against these Gram-positive strains ranged from 1–8 μg/ml. In the present study, Products A and B were inhibitory against *Streptococcus canis* at concentrations between 6.25–12.5 μg/ml, again slightly higher than what was achieved in the comparison Moscoso et al., study. The higher MIC values of *Streptococcus canis* as compared to the *Staphylococcus* spp. may be due to the interaction with serum components in the culture media used with the *Streptococcus* spp. In the Moscoso study, MHB was supplemented with 2.5% horse blood, and in the present study, MHB was supplemented with 5% sheep’s blood. The interaction with serum components has been shown to reduce the effective concentration of CSA-13 in blood-product supplemented media [48].

In 2008, Chin et al. evaluated CSA-13 against clinical isolates of *Pseudomonas aeruginosa*. The MIC$_{50}$ of the fifty clinical isolates in that study was 16 μg/ml [24]. The MIC of Products A and B against the *Pseudomonas aeruginosa* isolates in the current study ranged from 6.25–25 μg/ml. Interestingly, Chin et al. also evaluated tobramycin and ciprofloxacin against the same clinical isolates and achieved MIC$_{50}$ values of 1 and 2 μg/ml, respectively [24]. In the present study, the MIC of tobramycin was ≤ 0.36 and ranged for tobramycin between ≤ 0.36 and 5.8 μg/ml. Similar to the Chin study, CSA-13 in the present study was less inhibitory than

Fig 2. Cytotoxicity of ophthalmic products against CCL-60 cells, single 2-hour exposure. Tobramycin was used as the positive control. Cells were exposed to the commercial products for a single 2-hour exposure. Cell viability was expressed as percentage of absorbance in comparison to the negative control. A compound was considered toxic to the cell line in this experiment if ≤ 95% cell survival was recorded. Toxicity is indicated by (*).

https://doi.org/10.1371/journal.pone.0193217.g002
tobramycin, but similar in inhibition to the ofloxacin. The disparity in the MICs of the clinical *Pseudomonas aeruginosa* isolates between the Chin, et al. study and the present study could be related to the pathogenicity of the isolates used and/or the number of the isolates used.

The active ingredient in Product C is neutral SOW. However according to Sonoma Pharmaceuticals, the patented Microcyn® technology is no longer used to produce Product C (as indicated on their webpage). Two studies have evaluated the antimicrobial activity of neutral SOW. However, those studies used the patented Microcyn® technology when producing the active ingredient. To the authors’ knowledge, there are no studies that have evaluated the antimicrobial activity of the neutral SOW used in the current Product C. In 2005, Landa-Solis et al. showed that a stable SOW (Microcyn®) with a low oxychlorine content (51–85 ppm) and neutral pH was able to kill *S. aureus* and *P. aeruginosa* within 20 seconds [38]. In 2010, Sauer et al. demonstrated that exposure of *P. aeruginosa* to neutral SOW (Microcyn®) for 20 seconds (during exponential phase) with oxychlorine concentrations of 80, 125 and 200 ppm were sufficient to reduce viability by more than 5 logs. Further, exposure for 10 minutes to neutral SOW with oxychlorine concentrations of 125 and 200 ppm was sufficient to eradicate stationary phase *P. aeruginosa* [32]. In the present study, Product C was unable to inhibit growth of any of the bacterial organisms tested over a 24-hour period and a free available chlorine or oxychlorine concentration of 150 ppm. While the time-kill assay used in the Landa-Solis and Sauer studies differed from the assay (MIC) used in the present study to measure inhibition of bacterial growth, there is a stark difference in growth inhibition between the studies. Perhaps the different method for producing the SOW is responsible for this difference.

---

**Fig 3. Cytotoxicity of ophthalmic products against J774A.1 cells, four 5-minute exposures.** Tobramycin was used as the positive control. Cells were exposed to the commercial products for 5 minutes, 4 separate times. Cell viability was expressed as percentage of absorbance in comparison to the negative control. A compound was considered toxic to the cell line in this experiment if ≤ 95% cell survival was recorded. Toxicity is indicated by (*).

https://doi.org/10.1371/journal.pone.0193217.g003
The cytotoxic effects of Products A and B were evaluated against a murine macrophage-like cell line (J774.1) and a rabbit corneal fibroblast cell line (CCL-60) using the MTS assay. Results revealed toxicities similar to slightly less than the positive control, tobramycin for the J774.1 assays and similar to slightly more than tobramycin for the CCL-60 assays. Tobramycin was selected as the positive control due to the lower toxicity compared to gentamicin and ofloxacin [49, 50]. While less toxic than tobramycin, the toxicities of Products A and B may have been diminished due to an interaction with the fetal bovine serum used in the J774.1 MTS assay. As discussed previously, the interaction with serum components has been shown to reduce the effective concentration of CSAs in blood-product supplemented media [48]. Product A was more toxic than Product B and tobramycin in both CCL-60 assays. As the chemical composition of Products A and B is the same, the difference in toxicities between the two compounds may be related to stability and shelf-life as Product B was older than Product A.

Product C was only cytotoxic in the single 2-hour exposure assay when placed undiluted on both the J774.1 and CCL-60 cell cultures. In the four 5-minute exposure assays using the J774.1 assay, Product C was cytotoxic when undiluted and diluted 1:1 (50%) with the DMEM media supplemented with 10% fetal bovine serum. Product C was cytotoxic in the CCL-60 assay only when placed on cell culture undiluted. To the authors’ knowledge, there are no previous studies evaluating the effects of a neutral SOW against the J774.1 murine macrophage-like cell line or the CCL-60 rabbit corneal fibroblast cell line.

Product C is composed of water and a combination of hypochlorous acid and sodium hypochlorite, similar to a dilute bleach. A study in 2001 evaluated the shelf life of undiluted bleach and determined that undiluted bleach was able to maintain 90 per cent of its original

---

**Fig 4. Cytotoxicity of ophthalmic products against CCL-60 cells, four 5-minute exposures.** Tobramycin was used as the positive control. Cells were exposed to the commercial products for 5 minutes, 4 separate times. Cell viability was expressed as percentage of absorbance in comparison to the negative control. A compound was considered toxic to the cell line in this experiment if ≤ 95% cell survival was recorded. Toxicity is indicated by (*).

https://doi.org/10.1371/journal.pone.0193217.g004
strength for at least six months [50]. However, dilute bleach in clear syringes exposed to sunlight demonstrated a rapid loss of chlorine content [50]. The authors concluded that dilute bleach should not be stored for more than three months [51]. The Product C used in this study was purchased off of the shelf in a clear blue bottle. The length of time since the product was manufactured was unknown. Perhaps degradation of the hypochlorous acid was the reason for the diminished activity in this study.

We have demonstrated the potential utility of Products A and B against clinical isolates from the eye and their safety when placed on cell culture. The CSAs were similar to slightly less effective than common commercial antibiotics, but still demonstrated moderate to potent bactericidal activity and toxicities similar to a known, minimally toxic, ophthalmic antibiotic solution, tobramycin. However, the neutral super-oxidized water, Product C, was an ineffective antimicrobial alternative. Moving forward, Products A and B may offer alternatives or co-treatment modalities to current approaches and have the potential to be used for treatment of infections of the ocular surface caused by common bacterial flora. However further investigations are needed.

Supporting information
S1 Table. Description of clinical isolates used in the study. (DOCX)

Author Contributions
Conceptualization: Benjamin E. Bergstrom, Ahmed Abdelkhalek, Waleed Younis, Wendy M. Townsend, Mohamed N. Seleem.
Investigation: Benjamin E. Bergstrom, Ahmed Abdelkhalek, Waleed Younis.
Methodology: Benjamin E. Bergstrom, Ahmed Abdelkhalek, Waleed Younis, Mohamed N. Seleem.
Resources: G. Kenitra Hammac.
Supervision: Wendy M. Townsend, Mohamed N. Seleem.
Writing – original draft: Benjamin E. Bergstrom.
Writing – review & editing: Ahmed Abdelkhalek, Wendy M. Townsend, Mohamed N. Seleem.

References
1. Kang MH, Chae MJ, Yoon JW, Lee SY, Yoo JH, Park HM. Resistance to fluoroquinolones and methicillin in ophthalmic isolates of Staphylococcus pseudintermedius from companion animals. Can Vet J. 2014; 55: 678–682. PMID: 24982521
2. LoPinto AJ, Mohammed HO, Ledbetter EC. Prevalence and risk factors for isolation of methicillin-resistant Staphylococcus in dogs with keratitis. Vet Ophthalmol. 2015; 18: 297–303. https://doi.org/10.1111/vop.12200 PMID: 25130050
3. Mouney MC, Stiles J, Townsend WM, Guptill L, Weese JS. Prevalence of methicillin-resistant Staphylococcus spp. in the conjunctival sac of healthy dogs. Vet Ophthalmol. 2015; 18: 123–126. https://doi.org/10.1111/vop.12130 PMID: 24299189
4. Suter A, Voelter K, Spiess BM, Schmitt S, Wittenbrink MM, Pot SA. Septic keratitis in dogs, cats and horses in Switzerland; causative bacteria and antibiotic susceptibility. In: Proceedings of the 47th Annual Conference of the American College of Veterinary Ophthalmologists; 2016; Monterey, California, USA. p.32.
5. Martinez JA, da Costa PD. Evaluation of bacterial isolates and antibiotic susceptibility in cats and dogs presented with ulcerative keratitis to a referring practice in New Orleans, LA between 2011 and 2015. In: Proceedings of the 47th Annual Conference of the American College of Veterinary Ophthalmologists; 2016; Monterey, California, USA. p.35.

6. van 't Hof W, Veerman EC, Helmerhorst EJ, Amerongen AV. Antimicrobial peptides: properties and applicability. Biol Chem. 2001; 382: 597–619. https://doi.org/10.1515/BC.2001.072 PMID: 11405223

7. Shai Y. Mode of action of membrane active antimicrobial peptides. Biopolymers. 2002; 66: 236–248. https://doi.org/10.1002/bip.1026 PMID: 12491537

8. Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med. 2002; 252: 91–106. PMID: 12190884

9. Arigoni F, Talabot F, Peitsch M, Edgerton MD, Meldrum E, Allet E, et al. A genome-based approach for the identification of essential bacterial genes. Nat Biotechnol. 1998; 16: 851–856. https://doi.org/10.1038/nbt0998-851 PMID: 9743119

10. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev. 2006; 19: 491–511. https://doi.org/10.1128/CMR.00056-05 PMID: 16847082

11. Mohammad H, Thangamani S, Selee M. Antimicrobial peptides and peptidomimetics—potent therapeutic allies for staphylococcal infections. Curr Pharm Des. 2015; 21: 2073–2088. PMID: 25760338

12. Tincu JA, Menzel LP, Azimov R, Sands J, Waring AJ, et al. Plicatamide, an antimicrobial octapeptide from Styela plicata hemocytes. J Biol Chem. 2003; 278: 13546–13553. https://doi.org/10.1074/jbc.M211332200 PMID: 12569105

13. Pinheiro da Silva F, Machado MC. Antimicrobial peptides: clinical relevance and therapeutic implications. Peptides. 2012; 36: 308–314. https://doi.org/10.1016/j.peptides.2012.05.014 PMID: 22659161

14. Lee IH, Cho Y, Lehrer RI. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect Immun. 1997; 65: 2898–2903. PMID: 9199465

15. Papagianni M. Ribosomally synthesized peptides with antimicrobial properties: biosynthesis, structure, function, and applications. Biotechnol Adv. 2003; 21: 465–499. PMID: 14499150

16. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol. 2013; 31: 379–382. https://doi.org/10.1038/nbt.2572 PMID: 23657384

17. Ding B, Yin N, Liu Y, Cardenas-Garcia J, Evason R, Orsak T, et al. Origins of cell selectivity of cationic steroid antibiotics. J Am Chem Soc. 2004; 126: 13642–13648. https://doi.org/10.1021/ja046909p PMID: 15493921

18. Bruch MD, CajaI Y, Koh JT, Jain MK. Higher-order structure of polymyxin B: the functional significance of topological flexibility. J Am Chem Soc. 1999; 121: 11993–12004.

19. Thomas CJ, Gangadhar BP, Surolia N, Surolia A. Kinetics and mechanism of the recognition of endotoxin by polymyxin B. J Am Chem Soc. 1998; 120: 12428–12434.

20. Srimal S, Surolia N, Balasubramanian S, Surolia A. Titration calorimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem J. 1996; 315: 679–686. PMID: 8615847

21. Savage PB, Li C, Taotafa U, Ding B, Guan Q. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett. 2002; 217: 1–7. PMID: 12445638

22. Li C, Peters AS, Meredith EL, Allman GW, Savage PB. Design and synthesis of potent sensitizers of gram-negative bacteria on a cholic acid scaffolding. J Am Chem Soc. 1998; 120: 2961–2962.

23. Walker S, Sofia MJ, Kakarla R, Kogan NA, Wierichs L, Longley CB, et al. Cationic facial amphipiles: a promising class of transfection agents. Proc Natl Acad Sci U S A. 1996; 93: 1585–1590. PMID: 8643675

24. Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. J Antimicrob Chemother. 2008; 61: 365–370. https://doi.org/10.1093/jac/dkm457 PMID: 18079128

25. Chin JN, Rybak MJ, Cheung CM, Savage PB. Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007; 51: 1268–1273. https://doi.org/10.1128/AAC.01325-06 PMID: 17210765

26. Saha S, Savage PB, Bal M. Enhancement of the efficacy of erythromycin in multiple antibiotic-resistant gram-negative bacterial pathogens. J Appl Microbiol. 2008; 105: 822–828. https://doi.org/10.1111/j.1365-2672.2008.03820.x PMID: 18452333

27. Howell MD, Streib JE, Kim BE, Lesley LJ, Dunlap AP, Geng D, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol. 2009; 129: 2668–2675. https://doi.org/10.1038/jid.2009.120 PMID: 19516269
28. Epand RF, Savage PB, Epand RM. Bacterial lipid composition and the antimicrobial efficacy of cationic steroid compounds (Ceragenins). Biochim Biophys Acta. 2007; 1768: 2500–2509. https://doi.org/10.1016/j.bbamem.2007.05.023 PMID: 17599802

29. Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother. 2010; 54: 3708–3713. https://doi.org/10.1128/AAC.00380-10 PMID: 20585129

30. Polat ZA, Savage PB, Genberg C. In vitro amoebicidal activity of a ceragenin, cationic steroid antibiotic-13, against Acanthamoeba castellani and its cytotoxic potential. J Ocul Pharmacol Ther. 2011; 27: 1–5. https://doi.org/10.1089/jop.2010.0041 PMID: 21142940

31. Nagant C, Pitts B, Stewart PS, Feng Y, Savage PB, Epand RM. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob Agents Chemother. 2010; 54: 3708–3713. https://doi.org/10.1128/AAC.00380-10 PMID: 20585129

32. Sampson MN, Muir AV. Not all super-oxidized waters are the same. J Hosp Infect. 2002; 52: 228–229.

33. Rutala WA, Weber DJ. New disinfection and sterilization methods. Emerg Infect Dis. 2001; 7: 348–353. https://doi.org/10.3201/eid0702.010701 PMID: 11294738

34. Iwasawa A, Nakamura Y. Bactericidal effect of acidic electrolyzed water—comparison of chemical acidic sodium hydrochloride (NaOCl) solution. Kansenshogaku Zasshi. 1996; 70: 915–922. PMID: 8921674

35. Len SV, Hung YC, Chung D, Anderson JL, Erickson MC, Morita K. Effects of storage conditions and pH on chlorine loss in electrolyzed oxidizing (EO) water. J Agric Food Chem. 2002; 50: 209–212. PMID: 11754569

36. Landa-Solis C, Gonzalez-Espinosa D, Guzman-Soriano B, Snyder M, Reyes-Teran G, Torres K, et al. Microcyn: a novel superoxidized water with neutral pH and disinfectant activity. J Hosp Infect. 2005; 61: 291–299. https://doi.org/10.1016/j.jhin.2005.04.021 PMID: 16242210

37. Sekiya S, Ohmori K, Harii K. Treatment of infectious skin defects or ulcers with electrolyzed strong acid aqueous solution. Artif Organs. 1997; 21: 32–38. PMID: 9012904

38. Inoue Y, Endo S, Kondo K, Ito H, Omori H, Saito K. Trial of electrolyzed strong acid aqueous solution lavage in the treatment of peritonitis and intraperitoneal abscess. Artif Organs. 1997; 21: 28–31. PMID: 9012903

39. Ohno H, Higashidate M, Yokosuka T. Mediastinal irrigation with superoxidized water after open-heart surgery: the safety and pitfalls of cardiovascular surgical application. Surg Today. 2000; 30: 1055–1056. https://doi.org/10.1007/s10592-000-0028-8 PMID: 11110409

40. Nelson D. Newer technologies for endoscope disinfection: electrolyzed acid water and disposable-component endoscope systems. Gastrointest Endosc Clin N Am. 2000; 10: 319–328. PMID: 10683217

41. Sakashita M, Iwasawa A, Nakamura Y. Antimicrobial effects and efficacy on habitually hand-washing of strong acidic electrolyzed water—a comparative study of alcoholic antiseptics and soap and tap water. Kansenshogaku Zasshi. 2002; 76: 373–377. PMID: 12073573

42. Kapur V, Marwaha AK. Evaluation of effect and comparison of superoxidized solution (oxum) v/s povidone iodine (betadine). Indian J Surg. 2011; 73: 48–53. https://doi.org/10.1007/s12262-010-0189-y PMID: 22211038

43. Martínez-Munive A. Super-oxidized water (Microcyn 60) for mesh hemioplasty in grossly contaminated fields: an experimental study. In: Proceedings of American College of Surgeons 91st Annual Clinical Congress; 2005; San Francisco, California, USA. p.190.

44. CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standards- Tenth edition. CLSI document M07-A10. Wayne, PA: Clinical and Laboratory Standards Institute; 2015.

45. Moscoso M, Esteban-Torres M, Menendez M, Garcia E. In vitro bactericidal and bacteriolytic activity of ceragenin CSA-13 against planktonic cultures and biofilms of Streptococcus pneumoniae and other pathogenic streptococci. PLoS One. 2014; 9: e101037. https://doi.org/10.1371/journal.pone.0101037 PMID: 25006964
49. Nelson JD, Silverman V, Lima PH, Beckman G. Corneal epithelial wound healing: a tissue culture assay on the effect of antibiotics. Curr Eye Res. 1990; 9: 277–285. https://doi.org/10.3109/02713689009044524 PMID: 2347205

50. Seitz B, Hayashi S, Wee WR, LaBree L, McDonnell PJ. In vitro effects of aminoglycosides and fluoroquinolones on keratocytes. Invest Ophthalmol Vis Sci. 1996; 37: 656–665. PMID: 8595966

51. Clarkson RM, Moule AJ, Podlich HM. The shelf-life of sodium hypochlorite irrigating solutions. Aust Dent J, 2001. 46(4): 269–276. PMID: 11838874